Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe

Dravet syndrome (DS) is a severe, rare, and complex developmental and epileptic encephalopathy affecting 1 in 16 000 live births and characterized by a drug‐resistant epilepsy, cognitive, psychomotor, and language impairment, and behavioral disorders. Evidence suggests that optimal treatment of seizures in DS may improve outcomes, even though neurodevelopmental impairments are the likely result of both the underlying genetic variant and the epilepsy. We present an updated guideline for DS diagnosis and treatment, taking into consideration care of the adult patient and nonpharmaceutical therapeutic options for this disease. This up‐to‐date guideline, which is based on an extensive review of the literature and culminates with a new treatment algorithm for DS, is a European consensus developed through a survey involving 29 European clinical experts in DS. This guideline will serve professionals in their clinical practice and, as a consequence, will benefit DS patients and their families.

[1]  C. Chiron,et al.  Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome , 2021, Expert opinion on drug safety.

[2]  D. Andrade,et al.  A systematic review of adults with Dravet syndrome , 2021, Seizure.

[3]  D. Friedman,et al.  Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder , 2021, Annals of clinical and translational neurology.

[4]  Manisha N. Patel,et al.  Enhancing glucose metabolism via gluconeogenesis is therapeutic in a zebrafish model of Dravet syndrome , 2021, Brain communications.

[5]  E. Mercuri,et al.  Multicenter prospective longitudinal study in 34 patients with Dravet syndrome: Neuropsychological development in the first six years of life , 2021, Brain and Development.

[6]  I. McGregor,et al.  Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. , 2021, ACS chemical neuroscience.

[7]  S. Czuczwar,et al.  Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome , 2020, Expert opinion on drug discovery.

[8]  C. Gamble,et al.  Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT. , 2020, Health technology assessment.

[9]  M. D'souza,et al.  Nanoparticle encapsulated oxytocin increases resistance to induced seizures and restores social behavior in Scn1a-derived epilepsy , 2020, Neurobiology of Disease.

[10]  Tara R. Sadoway,et al.  Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine , 2020, Epilepsia.

[11]  R. Guerrini,et al.  Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real‐world study , 2020, Epilepsia.

[12]  D. Lowenstein,et al.  Prehospital midazolam use and outcomes among patients with out-of-hospital status epilepticus , 2020, Neurology.

[13]  W. Park,et al.  Genetic Diagnosis of Dravet Syndrome Using Next Generation Sequencing-Based Epilepsy Gene Panel Testing. , 2020, Annals of clinical and laboratory science.

[14]  M. Giladi,et al.  Convulsive seizures and some behavioral comorbidities are uncoupled in the Scn1aA1783V Dravet syndrome mouse model , 2020, Epilepsia.

[15]  I. Aznarez,et al.  Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome , 2020, Science Translational Medicine.

[16]  Li Jiang,et al.  Efficacy of the ketogenic diet in patients with Dravet syndrome: A meta-analysis , 2020, Seizure.

[17]  Sebastien M. Weyn-Vanhentenryck,et al.  Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression , 2020, Nature Communications.

[18]  H. Lerche,et al.  Faculty Opinions recommendation of dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[19]  K. Yamakawa,et al.  CRISPR/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice , 2020, Neurobiology of Disease.

[20]  K. Commons,et al.  A 5‐HT1D‐receptor agonist protects Dravet syndrome mice from seizure and early death , 2020, The European journal of neuroscience.

[21]  G. King,et al.  A selective naV1.1 activator with potential for treatment of dravet syndrome epilepsy. , 2020, Biochemical pharmacology.

[22]  I. Vetter,et al.  NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome , 2020, PloS one.

[23]  Zhe Jin,et al.  The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome , 2020, Frontiers in Pharmacology.

[24]  D. Kullmann,et al.  dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  Benjamin D. Sellers,et al.  GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer’s Disease Models , 2020, Cell reports.

[26]  J. H. Cross,et al.  Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial , 2019, The Lancet.

[27]  E. Wirrell,et al.  Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens , 2019, JAMA neurology.

[28]  I. Scheffer,et al.  SCN1A‐related phenotypes: Epilepsy and beyond , 2019, Epilepsia.

[29]  L. Lagae,et al.  Dravet syndrome: Treatment options and management of prolonged seizures , 2019, Epilepsia.

[30]  T. Granata,et al.  Dravet syndrome: Early electroclinical findings and long‐term outcome in adolescents and adults , 2019, Epilepsia.

[31]  Nathan Fountain,et al.  Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. , 2019, The New England journal of medicine.

[32]  D. Rokyta,et al.  Venom Peptides with Dual Modulatory Activity on the Voltage-Gated Sodium Channel NaV1.1 Provide Novel Leads for Development of Antiepileptic Drugs. , 2019, ACS pharmacology & translational science.

[33]  J. Chae,et al.  Diagnostic Yield of Epilepsy Panel Testing in Patients With Seizure Onset Within the First Year of Life , 2019, Front. Neurol..

[34]  T. Mayer,et al.  Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: A multicenter cohort study from Germany and review of literature , 2019, Epilepsy & Behavior.

[35]  R. Matthews,et al.  Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial , 2019, The Journal of Emergency Medicine.

[36]  D. Pilz,et al.  Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort , 2019, Brain : a journal of neurology.

[37]  Yuehua Zhang,et al.  The Efficacy of Ketogenic Diet in 60 Chinese Patients With Dravet Syndrome , 2019, Front. Neurol..

[38]  C. Gamble,et al.  Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial , 2019, The Lancet.

[39]  C. Frassoni,et al.  A two-hit story: Seizures and genetic mutation interaction sets phenotype severity in SCN1A epilepsies , 2019, Neurobiology of Disease.

[40]  K. Desloovere,et al.  Gait deviations in patients with dravet syndrome: A systematic review. , 2019, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[41]  Chen Chen,et al.  Efficacy of the ketogenic diet in Chinese children with Dravet syndrome: A focus on neuropsychological development , 2019, Epilepsy & Behavior.

[42]  T. Polster.  Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome , 2019, Epilepsy & Behavior.

[43]  N. Knoers,et al.  Outcomes and comorbidities of SCN1A-related seizure disorders , 2019, Epilepsy & Behavior.

[44]  B. Ceulemans,et al.  More daytime sleepiness and worse quality of sleep in patients with Dravet Syndrome compared to other epilepsy patients. , 2019, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[45]  O. Devinsky,et al.  Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial , 2018, Epilepsia.

[46]  P. Striano,et al.  Emerging drugs for the treatment of Dravet syndrome , 2018, Expert opinion on emerging drugs.

[47]  C. Bentes,et al.  Trazodone: A New Antiepileptic Drug for Dravet Syndrome? , 2018, International Journal of Epilepsy.

[48]  C. Reid,et al.  Selective NaV1.1 activation rescues Dravet syndrome mice from seizures and premature death , 2018, Proceedings of the National Academy of Sciences.

[49]  W. Xin-hua,et al.  Prospective study of the efficacy of a ketogenic diet in 20 patients with Dravet syndrome , 2018, Seizure.

[50]  Anup D. Patel,et al.  Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results , 2018, Epilepsia.

[51]  N. Knoers,et al.  Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A‐related seizure phenotypes , 2018, Epilepsia.

[52]  I. Scheffer,et al.  Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group , 2018, Epilepsia open.

[53]  G. Carvill,et al.  Parental Mosaicism in "De Novo" Epileptic Encephalopathies. , 2018, The New England journal of medicine.

[54]  Qiong Wu,et al.  Ketogenic diet effects on 52 children with pharmacoresistant epileptic encephalopathy: A clinical prospective study , 2018, Brain and behavior.

[55]  I. Scheffer,et al.  Sleep problems in Dravet syndrome: a modifiable comorbidity , 2018, Developmental medicine and child neurology.

[56]  L. Lagae,et al.  Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey , 2018, Developmental medicine and child neurology.

[57]  S. Zuberi,et al.  Dravet syndrome and its mimics: Beyond SCN1A , 2017, Epilepsia.

[58]  M. Meskis,et al.  Dravet syndrome: Characteristics, comorbidities, and caregiver concerns , 2017, Epilepsy & Behavior.

[59]  Hoon-Chul Kang,et al.  Low glycemic index treatment in patients with drug-resistant epilepsy , 2017, Brain and Development.

[60]  Rongrui Tang,et al.  Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. , 2017, The New England journal of medicine.

[61]  Charles R. Yang,et al.  A small molecule activator of Nav1.1 channels increases fast‐spiking interneuron excitability and GABAergic transmission in vitro and has anti‐convulsive effects in vivo , 2017, The European journal of neuroscience.

[62]  H. Steiger,et al.  Efficacy of adjunctive vagus nerve stimulation in patients with Dravet syndrome: A meta-analysis of 68 patients , 2017, Seizure.

[63]  I. Scheffer,et al.  Fatal Cerebral Edema With Status Epilepticus in Children With Dravet Syndrome: Report of 5 Cases , 2017, Pediatrics.

[64]  G. Avanzini,et al.  Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations , 2017, Neurology.

[65]  E. Wirrell,et al.  Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel. , 2017, Pediatric neurology.

[66]  Luke P. Lee,et al.  Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome , 2017, Brain : a journal of neurology.

[67]  I. Scheffer,et al.  Dysarthria and broader motor speech deficits in Dravet syndrome , 2017, Neurology.

[68]  M. Hammer,et al.  Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with Dravet syndrome , 2017, Epilepsia.

[69]  I. Scheffer,et al.  Mortality in Dravet syndrome , 2016, Epilepsy Research.

[70]  Stacey B. B. Dutton,et al.  Huperzine A Provides Robust and Sustained Protection against Induced Seizures in Scn1a Mutant Mice , 2016, Front. Pharmacol..

[71]  E. Wirrell.  Treatment of Dravet Syndrome , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[72]  P. Camfield,et al.  Helping Families Cope with the Severe Stress of Dravet Syndrome , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[73]  O. Khorkova,et al.  Upregulation of Haploinsufficient Gene Expression in the Brain by Targeting a Long Non-coding RNA Improves Seizure Phenotype in a Model of Dravet Syndrome , 2016, EBioMedicine.

[74]  G. Carvill,et al.  Pitfalls in genetic testing: the story of missed SCN1A mutations , 2016, Molecular genetics & genomic medicine.

[75]  A. Basbaum,et al.  Selective spider toxins reveal a role for Nav1.1 channel in mechanical pain , 2016, Nature.

[76]  J. Hurst,et al.  Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis , 2016, Journal of Medical Genetics.

[77]  Anup D. Patel,et al.  Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial , 2016, The Lancet Neurology.

[78]  H. Kurahashi,et al.  Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes , 2016, Brain and Development.

[79]  E. Thiele,et al.  Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy , 2015, Epilepsia.

[80]  Linda J. Dalic,et al.  Lamotrigine can be beneficial in patients with Dravet syndrome , 2015, Developmental medicine and child neurology.

[81]  A. Mühlebner,et al.  Efficacy and tolerability of the ketogenic diet in Dravet syndrome – Comparison with various standard antiepileptic drug regimen , 2015, Epilepsy Research.

[82]  L. Mucke,et al.  Tau Reduction Prevents Disease in a Mouse Model of Dravet Syndrome , 2014, Annals of neurology.

[83]  A. Lang,et al.  Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome , 2014, Neurology.

[84]  I. Jambaqué,et al.  Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy , 2013, Orphanet Journal of Rare Diseases.

[85]  Scott C. Baraban,et al.  Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet Syndrome treatment , 2013, Nature Communications.

[86]  L. Laux,et al.  The Ketogenic Diet in Dravet Syndrome , 2013, Journal of child neurology.

[87]  S. Zuberi,et al.  SCN1A Genetic Test for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy and its Clinical Subtypes) for use in the Diagnosis, Prognosis, Treatment and Management of Dravet Syndrome , 2013, PLoS currents.

[88]  T. Mayer,et al.  Concentrations of Stiripentol in Children and Adults With Epilepsy: The Influence of Dose, Age, and Comedication , 2012, Therapeutic drug monitoring.

[89]  S. Zuberi,et al.  Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. , 2012, Brain : a journal of neurology.

[90]  I. Scheffer,et al.  Progressive gait deterioration in adolescents with Dravet syndrome. , 2012, Archives of neurology.

[91]  L. Lagae,et al.  Successful use of fenfluramine as an add‐on treatment for Dravet syndrome , 2012, Epilepsia.

[92]  M. Staudt,et al.  Bromide in Patients with SCN1A-Mutations Manifesting as Dravet Syndrome , 2012, Neuropediatrics.

[93]  M. Carniello,et al.  Long-term follow-up of the ketogenic diet for refractory epilepsy: Multicenter Argentinean experience in 216 pediatric patients , 2011, Seizure.

[94]  S. Zuberi,et al.  Comorbidities and predictors of health‐related quality of life in Dravet syndrome , 2011, Epilepsia.

[95]  Beppie van den Bogaerde,et al.  Clinical practice , 2011, European Journal of Pediatrics.

[96]  O. Dulac,et al.  Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: A prospective pilot study , 2011, Epilepsia.

[97]  C. Dravet.  The core Dravet syndrome phenotype , 2011, Epilepsia.

[98]  T. Granata.  Comprehensive care of children with Dravet syndrome , 2011, Epilepsia.

[99]  B. Ceulemans.  Overall management of patients with Dravet syndrome , 2011, Developmental medicine and child neurology.

[100]  P. Genton,et al.  Dravet syndrome: The long‐term outcome , 2011, Epilepsia.

[101]  R. Guerrini,et al.  Cognitive development in Dravet syndrome: A retrospective, multicenter study of 26 patients , 2011, Epilepsia.

[102]  A. McGonigal,et al.  Generalized convulsive status epilepticus management in adults: A cohort study with evaluation of professional practice , 2010, Epilepsia.

[103]  N. Boddaert,et al.  Unusual consequences of status epilepticus in Dravet syndrome , 2010, Seizure.

[104]  Katsuhiro Kobayashi,et al.  A long‐term follow‐up study of Dravet syndrome up to adulthood , 2009, Epilepsia.

[105]  A. Arzimanoglou.  Dravet syndrome: From electroclinical characteristics to molecular biology , 2009, Epilepsia.

[106]  C. Depienne,et al.  Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients , 2008, Journal of Medical Genetics.

[107]  R. Scott,et al.  Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study , 2008, The Lancet Neurology.

[108]  C. Korff,et al.  Dravet Syndrome (Severe Myoclonic Epilepsy in Infancy): A Retrospective Study of 16 Patients , 2007, Journal of child neurology.

[109]  I. Scheffer,et al.  Severe myoclonic epilepsy of infancy (Dravet syndrome): Recognition and diagnosis in adults , 2006, Neurology.

[110]  O. Dulac,et al.  Topiramate in the Treatment of Highly Refractory Patients with Dravet Syndrome , 2006, Neuropediatrics.

[111]  C. Chiron,et al.  IN VITRO AND IN VIVO INHIBITORY EFFECT OF STIRIPENTOL ON CLOBAZAM METABOLISM , 2006, Drug Metabolism and Disposition.

[112]  E. Cesaroni,et al.  Complications of vagal nerve stimulation for epilepsy in children , 2006, Neurosurgical Review.

[113]  N. Fejerman,et al.  Ketogenic Diet in Patients with Dravet Syndrome , 2005, Epilepsia.

[114]  D. Nordli,et al.  Multidisciplinary Approach to Childhood Epilepsy: Exploring the Scientific Rationale and Practical Aspects of Implementation , 2004, Journal of child neurology.

[115]  M. Smyth,et al.  Complications of chronic vagus nerve stimulation for epilepsy in children. , 2003, Journal of neurosurgery.

[116]  G. Dellatolas,et al.  Efficacité et tolérance à long terme du stiripentol dans le traitement de l’épilepsie myoclonique sévère du nourrisson (syndrome de Dravet) , 2002 .

[117]  L. Lagae,et al.  De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. , 2001, American journal of human genetics.

[118]  O. Dulac,et al.  Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial , 2000, The Lancet.

[119]  D. Ferriero,et al.  Effect of prehospital treatment on the outcome of status epilepticus in children. , 1995, Pediatric neurology.

[120]  H. Gastaut,et al.  Treatment of self-induced photosensitive epilepsy with fenfluramine. , 1985, The New England journal of medicine.

[121]  O. Dulac,et al.  From genotype to phenotype in Dravet disease , 2017, Seizure.

[122]  Orrin Devinsky,et al.  Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. , 2017, The New England journal of medicine.

[123]  H. Oguni,et al.  Dravet syndrome (severe myoclonic epilepsy in infancy). , 2013, Handbook of clinical neurology.

[124]  N. Fejerman,et al.  Ketogenic diet in patients with Dravet syndrome and myoclonic epilepsies in infancy and early childhood. , 2005, Advances in neurology.

[125]  G. Avanzini,et al.  Clinical and genetic factors predicting Dravet syndrome in infants with SCN 1 A mutations , 2022 .